![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Orchid Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2024
Details:
Under the terms of this agreement, Takeda has granted Cipla non-exclusive patent licensing rights for the commercialization of Voltapraz (vonoprazan) in India.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Voltapraz
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 20, 2024
Details:
Lanreotide generic injection is approved by FDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Endocrinology Product Name: Somatuline Depot-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Details:
Under the partnership, Cipla will be responsible for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range, including Frisium (clobazam), a brand in the anti-epileptic medication category, in India.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Frisium
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2024
Details:
The partnership will allow Cipla to scale up the product, conduct the required studies, and seek regulatory approvals for the commercialization of amphotericin, which is being evaluated in the preclinical studies for the treatment of Fungal keratitis.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Central Drug Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 15, 2024
Details:
Under the amendment Cipla and Pulmatrix agreed to stop patient enrollment of the Ph2b study of PUR1900 (itraconazole) at 8 subjects and close the study. Cipla will take sole responsibility for development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis.
Lead Product(s): Itraconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PUR1900
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Pulmatrix
Deal Size: Undisclosed Upfront Cash: $22.0 million
Deal Type: Agreement January 08, 2024
Details:
Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Lead Product(s): Glycine,Calcium
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nozohaem
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Actor Pharma
Deal Size: $48.6 million Upfront Cash: $48.6 million
Deal Type: Acquisition September 05, 2023
Details:
Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Galvus
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2023
Details:
ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.
Lead Product(s): ETH45
Therapeutic Area: Rare Diseases and Disorders Product Name: ETH45
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ethris
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 29, 2022
Details:
Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Lead Product(s): Tamsulosin,Solifenacin Succinate
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022